Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study
about
Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcomaMorpholino-Mediated Isoform Modulation of Vascular Endothelial Growth Factor Receptor-2 (VEGFR2) Reduces Colon Cancer Xenograft Growth.Placental growth factor in cancer.(Lymph)angiogenic influences on hematopoietic cells in acute myeloid leukemia.Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized DosingPharmacokinetic drug evaluation of pazopanib for the treatment of uterine leiomyosarcomas.Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients.Systemic Treatment for Adults with Synovial Sarcoma.A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study.
P2860
Q26747666-ADD4BB6B-943D-44F3-BDEE-69E5B7EDA9EFQ34774917-6E4F5C74-7330-4154-BBF3-76271605EE73Q38258289-6E95ECE6-3DEB-42A8-8C89-DAEF9DC3CEB8Q38269954-A2F6A80C-535A-4A81-8D7D-C6C911EFC335Q38936104-7D8FB9C2-2F15-4B94-A05F-EBB8D611EB3CQ38968504-189BCFE3-7A4A-4866-AA5C-A02236D72BA6Q39415429-757912E9-A280-4835-AE84-1B38AB291DC6Q39480956-A40C7818-7896-4226-A74A-3BAA577E4F72Q52667763-78927157-CAB1-4B90-BCD2-AC9540156850Q55064836-619ACDB1-70ED-4DB3-BD7C-63AC366B4819
P2860
Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Pazopanib exposure decreases a ...... on: results of a phase I study
@ast
Pazopanib exposure decreases a ...... on: results of a phase I study
@en
type
label
Pazopanib exposure decreases a ...... on: results of a phase I study
@ast
Pazopanib exposure decreases a ...... on: results of a phase I study
@en
prefLabel
Pazopanib exposure decreases a ...... on: results of a phase I study
@ast
Pazopanib exposure decreases a ...... on: results of a phase I study
@en
P2093
P2860
P356
P1476
Pazopanib exposure decreases a ...... on: results of a phase I study
@en
P2093
A B Suttle
C M L van Herpen
F A L M Eskens
M J Boers-Sonderen
P de Bruijn
S Sleijfer
W T A van der Graaf
P2860
P2888
P304
P356
10.1038/BJC.2013.798
P407
P577
2013-12-24T00:00:00Z